- Home
- IRS vs COLL Comparison
IRS vs COLL Comparison
Compare IRS & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRS
- COLL
- Stock Information
- Founded
- IRS 1943
- COLL 2002
- Country
- IRS Argentina
- COLL United States
- Employees
- IRS N/A
- COLL N/A
- Industry
- IRS Homebuilding
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- IRS Real Estate
- COLL Health Care
- Exchange
- IRS Nasdaq
- COLL Nasdaq
- Market Cap
- IRS 1.1B
- COLL 1.0B
- IPO Year
- IRS 1994
- COLL 2015
- Fundamental
- Price
- IRS $14.37
- COLL $30.93
- Analyst Decision
- IRS Strong Buy
- COLL Strong Buy
- Analyst Count
- IRS 1
- COLL 5
- Target Price
- IRS $12.62
- COLL $43.60
- AVG Volume (30 Days)
- IRS 184.8K
- COLL 441.9K
- Earning Date
- IRS 02-11-2025
- COLL 02-20-2025
- Dividend Yield
- IRS 11.32%
- COLL N/A
- EPS Growth
- IRS N/A
- COLL 757.11
- EPS
- IRS N/A
- COLL 2.16
- Revenue
- IRS $370,002,935.00
- COLL $599,245,000.00
- Revenue This Year
- IRS N/A
- COLL $13.25
- Revenue Next Year
- IRS N/A
- COLL $18.14
- P/E Ratio
- IRS N/A
- COLL $14.24
- Revenue Growth
- IRS N/A
- COLL 9.62
- 52 Week Low
- IRS $7.32
- COLL $28.39
- 52 Week High
- IRS $17.67
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- IRS 41.44
- COLL 45.90
- Support Level
- IRS $14.30
- COLL $32.28
- Resistance Level
- IRS $15.70
- COLL $33.45
- Average True Range (ATR)
- IRS 0.73
- COLL 1.07
- MACD
- IRS -0.06
- COLL -0.16
- Stochastic Oscillator
- IRS 12.57
- COLL 2.05
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.